方法：选取2011-04/2012-10在荆门市中医医院眼科门诊确诊的50例50眼上皮型HSK患者，将其随机分为对照组和试验组两组。两组均予以1.5g/L更昔洛韦眼用凝胶滴眼，每日6次； 试验组在此基础予以重组人干扰素α-2b滴眼液滴眼，每日6次，用药疗程均为4wk。比较两组患者临床治愈率，角膜溃疡愈合时间，疼痛减轻时间以及视力改善情况等。

结果：两组患者治疗前的一般情况无显著差异(P>0.05)。试验组临床治愈率为69%； 对照组患者临床治愈率为42%； 试验组患者临床治愈率明显高于对照组，组间比较差异有统计学意义(P<0.05)； 试验组患者角膜溃疡愈合及疼痛减轻时间均明显优于对照(P<0.05)。

结论：重组人干扰素α-2b滴眼液联合更昔洛韦眼用凝胶治疗上皮型HSK疗效确切，能明显提高视力、临床治愈率，缩短病程，是目前治疗上皮型HSK较理想的方法。

METHODS: Totally 50 cases(50 eyes)with epithelial HSK diagnosed in Ophthalmology Department of Jingmen Traditional Chinese Medicine Hospital from April 2011 to October 2012 were enrolled. All the patients were divided into control group and experimental group randomly. Control group was treated by 1.5g/L ganciclovir ophthalmic gel, 6 times per day, while experimental group was treated by 1.5g/L ganciclovir ophthalmic gel combined with recombinant human interferon α-2b eye drops, 6 times per day. All patients were treated for 4 weeks. Then the therapeutic effects of two groups, including the cure rate, time of corneal ulcer healing, pain relief and vision improvement, were compared and analyzed.

RESULTS: No significant differences in general condition between two groups was detected before treatment(P>0.05).The therapeutic effects of experimental group was better than the control group. The cure rate was 69% for experimental group and 42% for control group. The clinical cure rate in experimental group was significantly higher than that of the control group, there was statistically significant difference between the two groups(P<0.05). The time for corneal ulcer healing and pain relief in experimental group was significantly shorter than that for the control group(P<0.05).

CONCLUSION: The application ofganciclovir ophthalmic gel combined with recombinant human interferon α-2b eye drops in epithelial herpes simplex viral keratitis, which improves visual acuity and the cure rate and shortens the course of disease, is the ideal treatment of epithelial herpes simplex viral keratitis at present.